Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPYD-guided and pharmacokinetics-guided 5-fluorouracil dosing in gastrointestinal cancer
NL-OMON52496Recruiting
- Sponsor
- Isala
- Start
- Jan 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fluorouracil and capecitabine in gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency (2 arms), sponsored by Isala. Primary endpoint: 5-fluorouracil steady-state clearance. Started Jan 2020; status: recruiting.
02
Drugs
fluorouracilcapecitabine
03
Conditions
gastrointestinal cancerdihydropyrimidine dehydrogenase deficiency
Beyond the preview
Go deeper on NL-OMON52496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52496.